{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Lin Y"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitor (ICI) and targeted therapy (TT) combinations have emerged as promising first-line treatments for unresectable or advanced hepatocellular carcinoma (u/aHCC), leveraging synergistic anti-tumor effects. However, the comparative efficacy and safety of ICI-TT regimens <i>versus</i> sorafenib or lenvatinib (S/L) monotherapy require further elucidation across larger patient populations. This meta-analysis synthesizes data from phase 3 trials to evaluate the clinical benefits and risks of first-line ICI-TT combination therapy in u/aHCC.<h4>Methods</h4>We conducted systematic searches in PubMed and major oncology conference proceedings up to June 10, 2025. Eligible studies were randomized phase 3 trials comparing first-line ICI-TT <i>versus</i> S/L mon"],"journal":["Frontiers in immunology"],"pagination":["1667793"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12568680"],"repository":["biostudies-literature"],"pubmed_title":["First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials."],"pmcid":["PMC12568680"],"pubmed_authors":["Liao Y","Shen J","Lin Y","Luo B"],"additional_accession":[]},"is_claimable":false,"name":"First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.","description":"<h4>Background</h4>Immune checkpoint inhibitor (ICI) and targeted therapy (TT) combinations have emerged as promising first-line treatments for unresectable or advanced hepatocellular carcinoma (u/aHCC), leveraging synergistic anti-tumor effects. However, the comparative efficacy and safety of ICI-TT regimens <i>versus</i> sorafenib or lenvatinib (S/L) monotherapy require further elucidation across larger patient populations. This meta-analysis synthesizes data from phase 3 trials to evaluate the clinical benefits and risks of first-line ICI-TT combination therapy in u/aHCC.<h4>Methods</h4>We conducted systematic searches in PubMed and major oncology conference proceedings up to June 10, 2025. Eligible studies were randomized phase 3 trials comparing first-line ICI-TT <i>versus</i> S/L mon","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-05T09:26:25.263Z","creation":"2026-05-15T03:12:48.385Z"},"accession":"S-EPMC12568680","cross_references":{"pubmed":["41169385"],"doi":["10.3389/fimmu.2025.1667793"]}}